Evidence map›Paper›PMID 27346937›Full record

ReviewJournal of preventive medicine and hygiene2016

Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden.

V Tisa, I Barberis, V Faccio, C Paganino, C Trucchi, M Martini, F Ansaldi

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in Journal of preventive medicine and hygiene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 4 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 4 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Influenza vaccine outcomes: a meta-analysis revealing morbidity benefits amid low infection prevention.European respiratory review : an official journal of the European Respiratory Society · 2025
    Pooled it
  2. Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

V TisaDepartment of Health Sciences, University of Genoa, Genoa, Italy;
I BarberisDepartment of Health Sciences, University of Genoa, Genoa, Italy;
V FaccioDepartment of Health Sciences, University of Genoa, Genoa, Italy;
C PaganinoDepartment of Health Sciences, University of Genoa, Genoa, Italy;
C TrucchiDepartment of Health Sciences, University of Genoa, Genoa, Italy;
M MartiniDepartment of Health Sciences, University of Genoa, Genoa, Italy;
F AnsaldiDepartment of Health Sciences, University of Genoa, Genoa, Italy;; IRCCS AOU S. Martino, IST Genoa, Italy.
University of Genoa · ITOspedale Policlinico San Martino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Influenza illness is caused by influenza A and influenza B strains. Although influenza A viruses are perceived to carry greater risk because they account for the majority of influenza cases in most seasons and have been responsible for influenza pandemics, influenza B viruses also impose a substantial public health burden, particularly among children and at-risk subjects. Furthermore, since the 2001-2002 influenza season, both influenza B lineages, B/Victoria-like viruses and B/Yamagata-like viruses have co-circulated in Europe. The conventional trivalent influenza vaccines have shown a limited ability to induce effective protection when major or minor mismatches between the influenza B vaccine component and circulating strains occur. For this reason, the inclusion of a second B strain in influenza vaccines may help to overcome the well-known difficulties of predicting the circulating B lineage and choosing the influenza B vaccine component. Two quadrivalent influenza vaccines, a live-attenuated quadrivalent influenza vaccine (Q/LAIV) and a split inactivated quadrivalent influenza vaccine (I/QIV), were first licensed in the US in 2012. Since their introduction, models simulating the inclusion of QIV in influenza immunization programs have demonstrated the substantial health benefits, in terms of reducing the number of influenza cases, their complications and mortality. In the near future, evaluations from simulation models should be confirmed by effectiveness studies in the field, and more costeffectiveness analyses should be conducted in order to verify the expected benefits.

Indexed as

Influenza A virusInfluenza B virusAdolescentAdultAgedChildEuropeHumansInfluenza, HumanInfluenza VaccinesMiddle AgedRiskVaccinationInfluenza VaccinesCost-effectivenessImmunogenicityQuadrivalent influenza vaccineSafety

Identifiers

PMID27346937
PMCPMC4910440
OpenAlexW2475131042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.